When will the Avalo Therapeutics (AVTX) CFO’s PSU-related shares fully vest?

The shares underlying the CFO’s performance stock units are scheduled to fully vest on August 19, 2028. Vesting remains contingent on his continued service with Avalo Therapeutics through that vesting date, as described in the Form 4 footnote disclosure.

Avalo Therapeutics (AVTX) CFO receives 39,900 PSU-linked shares in equity award

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Avalo Therapeutics, Inc. disclosed that its Chief Financial Officer, Christopher Ryan Sullivan, acquired 39,900 shares of Common Stock on May 21, 2026 in a grant/award transaction with a stated price of $0.0000 per share. Following this award, he directly holds 40,323 shares of Common Stock.

According to the accompanying disclosure, these shares relate to performance stock units (PSUs) originally granted on August 19, 2025, each representing a contingent right to receive one share of Common Stock upon achievement of specified performance goals. The Compensation Committee certified achievement of those goals on May 21, 2026, and the shares subject to the PSUs are scheduled to fully vest on August 19, 2028, subject to Sullivan’s continued service through that vesting date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Sullivan Christopher Ryan

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	39,900	$0.00	--

Holdings After Transaction: Common Stock — 40,323 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Shares acquired: 39,900 shares Price per share: $0.0000 per share Post-transaction holdings: 40,323 shares +3 more

6 metrics

Shares acquired 39,900 shares Grant/award of Common Stock on May 21, 2026

Price per share $0.0000 per share Reported transaction price for the award

Post-transaction holdings 40,323 shares Common Stock directly held after the transaction

PSU grant date August 19, 2025 Original grant date of performance stock units

Performance certification date May 21, 2026 Compensation Committee certified performance goals

Full vesting date August 19, 2028 Scheduled full vesting of PSU-related shares

Key Terms

performance stock units, PSUs, Compensation Committee, vesting

4 terms

performance stock units financial

"Represents performance stock units ("PSUs") granted to the Reporting Person on August 19, 2025."

Performance stock units are a type of company award that grants employees shares of stock only if certain performance goals are met. They motivate employees to work toward specific company achievements, aligning their interests with those of shareholders. For investors, they can influence a company's future stock supply and reflect management’s confidence in reaching key targets.

PSUs financial

"Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon the achievement of certain performance goals."

PSUs are company shares promised to employees or executives that only become actual stock if the business hits specific performance targets over a set period. For investors, PSUs matter because they link pay to measurable outcomes — similar to a conditional bonus that converts into ownership — which can influence management decisions, dilution of shares, and signals about confidence in future results.

Compensation Committee financial

"On May 21, 2026, the Compensation Committee of the Issuer certified achievement of such performance goals."

A compensation committee is a group within a company's leadership responsible for setting and reviewing how much top executives and employees are paid, including salaries, bonuses, and benefits. It matters to investors because fair and effective pay decisions can influence a company's performance, leadership motivation, and overall governance, helping ensure that the company’s management is aligned with shareholders’ interests.

vesting financial

"As a result, the shares subject to the PSUs shall fully vest on August 19, 2028, subject to the Reporting Person's continued service on such vesting date."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

05/26/2026 - 04:10 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sullivan Christopher Ryan

(Last)

(First)

(Middle)

C/O AVALO THERAPEUTICS, INC.

1500 LIBERTY RIDGE DRIVE, SUITE 321

(Street)

WAYNE

PENNSYLVANIA

19087

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Avalo Therapeutics, Inc. [ AVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/21/2026		A⁽¹⁾		39,900	A	$0	40,323	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents performance stock units ("PSUs") granted to the Reporting Person on August 19, 2025. Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon the achievement of certain performance goals. On May 21, 2026, the Compensation Committee of the Issuer certified achievement of such performance goals. As a result, the shares subject to the PSUs shall fully vest on August 19, 2028, subject to the Reporting Person's continued service on such vesting date.

	/s/ Christopher Sullivan	05/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Avalo Therapeutics (AVTX) CFO report in this Form 4?

Avalo Therapeutics’ CFO, Christopher Ryan Sullivan, reported an acquisition of 39,900 shares of Common Stock on May 21, 2026. The award was recorded at a price of $0.0000 per share and increased his direct holdings to 40,323 shares after the transaction.

How many Avalo Therapeutics (AVTX) shares does the CFO hold after this transaction?

After this grant, Avalo Therapeutics’ CFO directly holds 40,323 shares of Common Stock. This total reflects the addition of 39,900 shares received in the reported award transaction dated May 21, 2026, as disclosed in the Form 4 filing.

What are the performance stock units (PSUs) mentioned for Avalo Therapeutics (AVTX) CFO?

The CFO’s PSUs are equity awards granted on August 19, 2025, each representing a contingent right to one Common Share. They become earned upon achieving specified performance goals and then convert into shares according to the vesting schedule described in the disclosure.

When were Avalo Therapeutics (AVTX) CFO’s PSU performance goals certified?

The Compensation Committee certified achievement of the CFO’s PSU performance goals on May 21, 2026. This certification confirms that the performance conditions were met, allowing the PSU-related shares to follow the stated vesting timeline, subject to continued service requirements.

Was the Avalo Therapeutics (AVTX) CFO’s Form 4 transaction an open-market purchase?

No, the Form 4 transaction reflects a grant or award acquisition, not an open-market purchase. The filing shows 39,900 shares acquired at a price of $0.0000 per share, tied to previously granted performance stock units rather than a market buy.